{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:42:51Z","timestamp":1760985771257},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Under certain circumstances, clinicians treating patients with isavuconazole for invasive aspergillosis or mucormycosis may use therapeutic drug monitoring. However, the accuracy and reproducibility of the various assays used by different laboratories for the quantification of isavuconazole plasma concentrations have yet to be determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Human plasma samples spiked with known concentrations of isavuconazole were provided to 27 European laboratories that took part in a \u201cround-robin\u201d test (an interlaboratory test performed independently at least 2 times; 2 rounds performed in the current study). Assay methods included liquid chromatography\u2013tandem mass spectrometry (LC-MS\/MS), LC with ultraviolet detection (LC-UV), LC with fluorescence detection (LC-FL), and bioassay. The accuracy and reproducibility compared with the known concentrations for each sample in each round were compared overall, between assays, and between laboratories.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-seven laboratories participated in the study (LC-MS\/MS, n = 15; LC-UV; n = 9; LC-FL, n = 1; bioassay, n = 2). In round 1, for nominal concentrations of 1000, 1700, 2500, and 4000 ng\/mL, the mean (SD) determined concentrations were 1007 (183), 1710 (323), 2528 (540), and 3898 (842) ng\/mL, respectively. In round 2, for nominal concentrations of 1200, 1800, 2400, and 4000 ng\/mL, the mean (SD) determined concentrations were 1411 (303), 2111 (409), 2789 (511), and 4723 (798) ng\/mL, respectively. Over both rounds, determined concentrations were consistently within 15% of the nominal concentrations for 10 laboratories (LC-MS\/MS, n = 4; LC-UV, n = 5; bioassay, n = 1) and consistently exceeded the upper 15% margin for 7 laboratories (LC-MS\/MS and LC-UV, n = 3 each; LC-FL, n = 1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Alignment of methodologies among laboratories may be warranted to improve the accuracy and reproducibility of therapeutic drug measurements.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000632","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T11:19:47Z","timestamp":1555154387000},"page":"657-664","source":"Crossref","is-referenced-by-count":11,"title":["Interlaboratory Analysis of Isavuconazole Plasma Concentration Assays Among European Laboratories"],"prefix":"10.1097","volume":"41","author":[{"given":"Federico","family":"Pea","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Udine, and Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital, ASUIUD, Udine, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Krause","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Drug Monitoring, Center of Pharmacology, University Hospital of Cologne, Cologne, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hennart","sequence":"additional","affiliation":[{"name":"Toxicology and Genopathy Unit, CHU Lille, Lille, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Richardson","sequence":"additional","affiliation":[{"name":"Mycology Reference Centre Manchester, ECMM Excellence Centre of Medical Mycology, Manchester University NHS Foundation Trust, Manchester, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Meinitzer","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H. J.","family":"Wiesen","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Drug Monitoring, Center of Pharmacology, University Hospital of Cologne, Cologne, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Wiktorowicz","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Basel, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Spickermann","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Basel, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne S.","family":"Henriksen","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Basel, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Florl","year":"2011","journal-title":"Drugs."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations","volume":"9","author":"Natesan","year":"2016","journal-title":"Infect Drug Resist."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"e01037","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jpba.2017.07.040","article-title":"A simple high performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring of isavuconazole and four other antifungal drugs in human plasma samples","volume":"145","author":"Fatiguso","year":"2017","journal-title":"J Pharm Biomed Anal."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FTD.0000000000000438","article-title":"Reliable and easy-to-use liquid chromatography-tandem mass spectrometry method for simultaneous snalysis of fluconazole, isavuconazole, itraconazole, hydroxy-itraconazole, posaconazole, and voriconazole in human plasma and serum","volume":"39","author":"M\u00fcller","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2017.01.036","article-title":"An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples","volume":"1046","author":"Toussaint","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/jac\/dkw098","article-title":"Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints","volume":"71","author":"Kovanda","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.01276-09","article-title":"Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jchromb.2012.01.015","article-title":"Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection","volume":"887-888","author":"Wissen","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0000000000000523","article-title":"Development and validation of a chromatographic ultraviolet method for the quantification of isavuconazole in human plasma samples","volume":"40","author":"Cozzi","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"e4333","DOI":"10.1002\/bmc.4333","article-title":"A sensitive and validated HPLC-UV method for the quantitative determination of the new antifungal drug isavuconazole in human plasma","volume":"32","author":"Nannetti","year":"2018","journal-title":"Biomed Chromatogr."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"e00098","DOI":"10.1128\/mSphere.00098-17","article-title":"Implementation of isavuconazole in a fluorescence-based high-performance liquid chromatography kit allowing simultaneous detection of all four currently licensed mold-active triazoles","volume":"2","author":"J\u00f8rgensen","year":"2017","journal-title":"mSphere"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jpba.2009.06.030","article-title":"Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection","volume":"50","author":"Gordien","year":"2009","journal-title":"J Pharm Biomed Anal."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2012.12.028","article-title":"Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry","volume":"919-920","author":"Jourdil","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4172\/1948-593X.1000050","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of voriconazole and posaconazole in serum samples from patients with invasive mycoses","volume":"3","author":"Franceschi","year":"2011","journal-title":"J Bioanal Biomed."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.chroma.2009.11.060","article-title":"Signal suppression\/enhancement in high-performance liquid chromatography tandem mass spectrometry","volume":"1217","author":"Gosetti","year":"2010","journal-title":"J Chromatogr A."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:22:02Z","timestamp":1692051722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000632","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}